Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Winner - TheStreet

Bristol-Myers Squibb Company



) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 0.5%. By the end of trading, Bristol-Myers Squibb Company rose 22 cents (0.6%) to $34.95 on light volume. Throughout the day, 6.6 million shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 9.8 million shares. The stock ranged in a price between $34.48-$35.15 after having opened the day at $34.81 as compared to the previous trading day's close of $34.73. Other companies within the Health Care sector that increased today were:




), up 29.8%,




), up 22.7%,

CytRx Corporation



), up 17.9%, and




), up 17.3%.

  • ACTIVE STOCK TRADERS: Check out TheStreet's special offer for Real Money, headlined by Jim Cramer, now!

Bristol-Myers Squibb Company, a biopharmaceutical company, engages in the discovery, development, licensing, manufacturing, marketing, distribution, and sale of biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $59.07 billion and is part of the


industry. The company has a P/E ratio of 15.7, below the average drugs industry P/E ratio of 15.8 and below the S&P 500 P/E ratio of 17.7. Shares are down 0.8% year to date as of the close of trading on Tuesday. Currently there are 10 analysts that rate Bristol-Myers Squibb Company a buy, one analyst rates it a sell, and nine rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a


. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow.

On the negative front,

D Medical Industries



), down 19.2%,

K-V Pharmaceutical Company



), down 14.1%,

Questcor Pharmaceuticals



), down 13.7%, and




), down 12.1%, were all laggards within the health care sector with




) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider

Health Care Select Sector SPDR



) while those bearish on the health care sector could consider

ProShares Ultra Short Health Care